GlaxoSmithKline announced that the Food and Drug Administration approved its supplemental new drug application for Promacta (eltrombopag), a once-daily medication for patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.
The Food and Drug Administration on Thursday approved Zontivity (vorapaxar) tablets, an anti-platelet agent that's designed to decrease the tendency of platelets to clump together to form a blood clot.
Patients once considered "aspirin resistant" may not be resistant to aspirin after all, according to a study published online by Circulation, the journal of the American Heart Association. Rather, the protective coating around the aspirin to prevent stomach issues may be delaying the absorption of aspirin, leading clinicians to believe that patients are aspirin resistant.
Prescribers, patients and specialty care centers no longer will be required to enroll in safety monitoring programs for two drugs used to treat low platelet counts, following changes to their risk evaluation and mitigation strategies.